AstraZeneca PLC and Ionis Pharmaceuticals, Inc. hope to bring a best-in-class treatment for hereditary transthyretin-mediated amyloidosis (ATTR) to market, starting with ATTR polyneuropathy (ATTRv-PN), and have delivered longer-term results for eplontersen that could make their drug a strong competitor to Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran).
[Sidebar#SC148116]







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)